An article entitled "2020 Update on Management and Future Directions" was published in the journal "Clinical Lymphoma, Myeloma and Leukemia". You can see it here. 2020 Update on Management of WM
The latest consensus on treatment recommendations has been published, from the tenth International Workshop for Waldenström Macroglobulinaemia (IWWM-10). These consensus documents are, or should be, the basis for treatment everywhere. National drug approvals, and provincial funding decisions, should (in theory) be in broad agreement with this. IWWM Consensus Guidelines -- 2020
Although this may appear as "another commercial press release from a drug company", this goes a little bit deeper for WM patients in Canada. Beigene, having received priority status with Health Canada, is pursuing their approval for its 2nd-generation BTK-inhibitor, Zanubrutinib (Brukinsa®), for the treatment of WM. Once Health Canada's review is complete, and assuming it is accepted, then Zanubrutinib would be on the same footing for WM patients in Canada as Ibrutinib. Beigene will then apply to pCODR (see our very brief explanation of How Cancer Drugs Are Approved and Funded in Canada on our Canadian Questions Page), seeking [...]
